Protocol Ledger

NCT04043455 · Phase II · TERMINATED

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

Interventional Phase II clinical trial protocol NCT04043455 sponsored by Pfizer in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-07-24 Enrollment: 273 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04043455
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)273 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04043455
Protocol FieldVerified Registry Value
NCT IdentifierNCT04043455
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment273 participants (ACTUAL)
Registered Start Date2019-07-24
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI